ライフサイエンスコーパス: rash

1 ne-tazobactam was discontinued in 1 patient (rash).

2 group was precluded by adverse skin events (rash).

3 ts of poison ivy leaves) and outcomes (e.g., rash).

4 nly fever, increased transaminase levels and rash.

5 ncluding the presence of an erythema migrans rash.

6 conjunctivitis followed by a characteristic rash.

7 lmonary infection with grade 3 maculopapular rash.

8 ere fatigue, nausea, headache, insomnia, and rash.

9 papulopustular, and/or erythematous diffuse rash.

10 al report of a typical itchy and/or flexural rash.

11 one patient developed a grade 3 drug-related rash.

12 6 pigs including diarrhoea, emesis, and skin rash.

13 gthened the time to the most severe grade of rash.

14 (50%) required dose reduction, 7 because of rash.

15 sory ganglia 3 dpi, before the appearance of rash.

16 hylactic treatment of erlotinib-induced skin rash.

17 t pain, respiratory distress, and a purpuric rash.

18 vasertib were diarrhea, fatigue, nausea, and rash.

19 of eye irritation, respiratory illness, and rash.

20 roelastosis, 1 degrees CHB at birth and skin rash.

21 uired dose reduction for grade 3 fatigue and rash.

22 Only 2 patients had rash.

23 ms and the pattern of their erythema migrans rash.

24 nspecific fever, headache, and maculopapular rash.

25 The dose-limiting toxicity was grade 3 rash.

26 nted with undifferentiated fever or afebrile rash.

27 vomiting, muscle pain, lack of appetite, and rash.

28 ipant discontinued the study drug owing to a rash.

29 participant discontinued therapy owing to a rash.

30 pidermal inflammation in a broad spectrum of rashes.

31 ed below, to tattoo studio clients reporting rashes.

32 h Zika virus disease, 133 (94%) children had rash, 104 (74%) fever, 67 (48%) arthralgia, and 51 (36%)

33 de 3-4 treatment-related adverse events were rash (11 [19%] patients), creatinine phosphokinase eleva

34 grade 3-4 immune-related adverse events were rash (11 [8%] of 141 patients) and increased alanine ami

35 group), fatigue (16 [13%] vs 12 [10%]), and rash (13 [10%] vs nine [7%]).

36 ), infusion-related reaction (16 [20%]), and rash (13 [16%]).

37 e [25%], pruritus [17%], diarrhea [13%], and rash [13%]), and 10% (95% CI, 8% to 13%) experienced gra

38 group), diarrhoea (ten [14%] vs three [4%]), rash (14 [20%] vs 0), infection (four [6%] vs two [3%]),

39 The most significant grade 3-4 toxicity was rash (14% maculopapular, 8.6% acneiform).

40 itinib and 208 [33%] patients on sorafenib), rash (15 [2%] patients on sunitinib and 95 [15%] patient

41 [61.2%]), followed by burn (307 [23.0%]) and rashes (163 [12.2%]).

42 % aspartate aminotransferase), maculopapular rash (17%), and neutropenia (17%).

43 symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%).

44 % of patients, most commonly: fatigue (29%), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%)

45 P < .001), and less likely to present with a rash (2% vs 15%; P = .010).

46 gemcitabine and cisplatin group) and grade 3 rash (20 [4%] vs one [<1%]).

47 more high-grade hyperglycemia (40% v 9%) and rash (24% v 2%).

48 ned lots, 4.2% high-dose, 0.0% placebo), and rash (3.8% combined lots, 3.8% high-dose, 1.5% placebo).

49 itis (36%), nausea (36%), fatigue (31%), and rash (31%).

50 ever/neutropenia (45%), infection (47%), and rash (40%).

51 51.3% vs 44.8%), diarrhoea (42.2% vs 46.6%), rash (40.9%, both groups), arthralgia (39.1% vs 28.1%),

52 rexed and cisplatin group had more grade 3-4 rash (45 [15%] of 304 vs one [<1%] of 312 patients in th

53 hyperglycaemia (88 [15%] vs one [<1%]), and rash (45 [8%] vs none).

54 pheral neuropathy (50%), alopecia (49%), any rash (48%), decreased appetite (44%), and dysgeusia (40%

55 ted liver tests (6%), myelotoxicity (7%) and rash (5%).

56 ated adverse events resolved (most commonly, rash; 5.9%).

57 fatigue (81 [13%] vs 74 [20%]), and acne or rash (52 [8%] vs one [<1%]).

58 , 80% had gastrointestinal symptoms, 60% had rash, 56% had conjunctival injection, and 27% had mucosa

59 de) were diarrhea (including colitis) (64%), rash (58%), pyrexia (42%), nausea (38%), chills (36%), c

60 Rash (84 reports), itching (46 reports), and vomiting (3

61 common treatment-related adverse events were rash (89 [56%]), increased alanine aminotransferase conc

62 was defined as any recurrent eye disease or rash 90 days or more after quiescence of disease was not

63 Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%).

64 tattoos were 8.2 times as likely to report a rash (95% confidence interval, 3.1-22.1).

65 r syndrome is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histologica

66 ause of the expected occurrence of acne-like rash--a class effect of EGFR antibodies--that would have

67 Other common features were erythrodermic rash, abdominal distension, edema, and hepatitis.

68 ever and at least two of nausea or vomiting, rash, aches and pains, positive tourniquet test, leukope

69 The rash affected all parts of the body, with the face being

70 Skin rash also correlated with drug levels and tended to decr

71 ssion, resulted in only a mild and transient rash and a short-lived elevation of the body temperature

72 urine of patients with (1) erythema migrans rash and acute symptoms, (2) post treatment Lyme disease

73 {95.2-96.5%}]), whereas higher incidence of rash and angioedema were reported for protocols with <6

74 mans by infected mosquitoes and causes acute rash and arthritis, occasionally complicated by neurolog

75 adults and children based on the presence of rash and brain MRI findings.

76 Physical examination showed rash and cheilitis or conjunctivitis.

77 hose receiving afatinib alone, most commonly rash and diarrhea.

78 vels of clinical outcomes, ranging from mild rash and fever to severe neurological complications and

79 rus isolation from a Florida teenager with a rash and fever.

80 mplications, 88.4% displayed mild disease of rash and fever.

81 s syndrome, grade 4 hypotension with grade 3 rash and fevers, grade 4 aspartate aminotransferase (AST

82 VZV-immune RMs displayed no varicella rash and had lower SVV viral loads and earlier and stron

83 ggested a relationship between exposure, and rash and hyperglycemia.

84 st common grade 3 events were skin toxicity (rash and palmar-plantar erythrodysesthesia; five [4%]) a

85 Patients with ZIKV presented with rash and pruritus (69.2% each) more frequently than thos

86 e events were <10%, consisting of minor skin rash and pruritus associated with the patch.

87 nophilia increases the hazard rate of having rash and renal injury.

88 ivation, with virus antigens found in zoster rash and SVV DNA and antigens found in lungs, lymph node

89 o developed a severe (grade 3) maculopapular rash and terminated treatment.

90 There were expected adverse events of rash and transient lymphopenia.

91 e woman in the placebo group reported a skin rash and two women in the amoxicillin and clavulanic aci

92 Case-patients reported fever and rash and were either laboratory-confirmed or had an epid

93 ion characterized by long-lasting urticarial rashes and histopathologic findings of leukocytoclastic

94 two of three additional patients had grade 3 rashes and one had grade 3 AST elevation.

95 history includes urticaria or other pruritic rashes and reactions with features of IgE-mediated react

96 ities, hemorrhagic manifestations, petechial rash, and a severely dysregulated immune response.

97 tially severe symptoms including depression, rash, and anxiety.

98 associated with delayed engraftment, fever, rash, and central nervous system dysfunction.

99 luding: eight (13%) of 64 patients reporting rash, and colitis, gastritis, pancreatitis and arthritis

100 k of the well-known adverse events of fever, rash, and convulsions within the first 14 days.

101 t common adverse events included stomatitis, rash, and diarrhea.

102 ents in either group were fatigue, pruritus, rash, and diarrhea.

103 arget adverse effects, such as hypertension, rash, and diarrhea.

104 sferase, increased alanine aminotransferase, rash, and dyspnoea being the most common.

105 n kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third

106 All 122 patients had vesiculopustular rash, and fever, pruritus, headache, and lymphadenopathy

107 acterized by fever, polyarthralgia, myalgia, rash, and headache.

108 nia with dyshematopoiesis, autoinflammation, rash, and HLH.

109 verse events were fatigue, headache, nausea, rash, and insomnia.

110 ays), fever, depression, anorexia, petechial rash, and lymphopenia.

111 Adverse events (eg, lethargy, diarrhoea, rash, and nausea) improved during the first 3 months of

112 s that include severe joint and muscle pain, rashes, and fever, as well as prolonged periods of disab

113 , presenting with a constellation of fevers, rashes, and mucosal symptoms in many cases, which sugges

114 Given the presentation of fevers, rashes, and mucosal symptoms observed in many of these s

115 valence of any local adverse event (redness, rashes, and pain) or systemic adverse event (fever, alle

116 , including symptoms of fatigue, fever, skin rashes, and ulcers, was measured using the Systemic Lupu

117 the creatine phosphokinase level; acneiform rash; and paronychia.

118 o elucidating why EGFR/MEK inhibitor-induced rashes are often pustular and folliculocentric, this mec

119 Patients experienced fever, skin rash, arthralgia and conjunctivitis.

120 elf-limiting illness characterised by fever, rash, arthralgia, and conjunctivitis.

121 neration family with cold-induced urticarial rash, arthralgia, chills, headache and malaise associate

122 arriers experience cold-inducible urticarial rash, arthralgia, fever, and fatigue.

123 er the onset of signs and symptoms including rash, arthralgia, headache, pruritus, myalgia, and fever

124 Zika virus infection in children with fever, rash, arthralgia, or conjunctivitis, who reside in or ha

125 nt with travel to Haiti who developed fever, rash, arthralgias, and conjunctivitis.

126 pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache;

127 inical manifestations that include fever and rash, as well as multiple organ failure (liver, kidney,

128 des scapularis tick and the erythema migrans rash associated with Lyme disease.

129 endamustine in two (7%) patients and diffuse rash at 1.2 mg/kg brentuximab vedotin plus 70 mg/m(2) of

130 , FLG status, or report of an itchy flexural rash at 2 months.

131 ectant mother who had a febrile illness with rash at the end of the first trimester of pregnancy whil

132 ccine group developed a grade 3 erythematous rash at the injection site.

133 tion, characterized by an intensely pruritic rash at the site of contact with allergens like poison i

134 an disease were observed including petechial rash, blood coagulation dysfunction, and various biochem

135 major symptoms reported in both groups were rash by 26 mothers (65.0%), fever by 9 mothers (22.5%),

136 to distinguish smallpox from other pustular rashes by description alone.

137 treatment of the most common irAEs including rash, colitis, hepatitis, endocrinopathies, and pneumoni

138 The rash consisted of mild erythematous, non-scaling patches

139 ded experiences, may provide a mechanism for rash decision making in adolescents.

140 Disease Control and Prevention (CDC; fever, rash, desquamation, hypotension, and multi-system involv

141 er virus (VZV) infection, in whom chickenpox rash developed 2 days after surgery.

142 Zoster rash developed after 7 days in the monkey with the most

143 day for 4 weeks), reactive treatment (after rash developed, per grade of rash), or no treatment unle

144 The incidence of all grades of rash did not differ statistically among the three arms,

145 Trial withdrawals and adverse events of rash, dizziness, and dental discoloration were more freq

146 In the rituximab group, nausea and skin rash during infusion were common; transient acute arthri

147 ); and were less likely to have a history of rash during pregnancy (20.7% vs 61.4%, ratio 0.34 [95% C

148 and probable cases there was no history of a rash during pregnancy.

149 ase (three [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decrease

150 (three [8%]), hypertension (six [16%]), skin rash (eight [22%]), and pancreatitis (six [16%] patients

151 rade 3 toxicities included keratoacanthomas, rash, fatigue, and arthralgia.

152 eria for Schnitzler syndrome with urticarial rash, fever, arthralgia, and bone pain; 47% reported wei

153 3 (12%) reported an adverse event, including rash, fever, serum sickness, and anaphylaxis.

154 phosphokinase (five [10%]) and maculopapular rash (five [10%]).

155 ); fatigue (four [22%] of 18; cohort C); and rash (five [26%] of 19; cohort D).

156 events in phase 1b were fatigue (nine; 75%), rash (five; 42%), and chills, decreased appetite, diarrh

157 d elimination of infectious virus during the rash followed by slow elimination of viral RNA.

158 hyperglycaemia (seven [8%] of 92 patients), rash (four [4%]), and dyspnoea (three [3%]).

159 rse events considered treatment-related were rash (four [5%]) and dizziness (three [4%]).

160 ma and neutropenia (five [63%] of eight) and rash (four [50%] of eight) for patients with follicular

161 oup vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one

162 swelling, vesicular lesions (blisters), and rashes from days 1 to 42.

163 sociated with selumetinib included acneiform rash, gastrointestinal effects, and asymptomatic creatin

164 verse events of these grades were urticarial rash (grade 3, equally common in both groups), neutropen

165 nts under observation (grade 4 maculopapular rash, grade 3 nausea, grade 3 infection, grade 3 thrombo

166 We enrolled pregnant women in whom a rash had developed within the previous 5 days and tested

167 he, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, and leukopenia; fever

168 d cellular mechanisms of vemurafenib-induced rashes have remained largely elusive.

169 hilia were significantly more likely to have rash (hazard ratio [HR], 4.16; 95% CI, 2.54-6.83; P < .0

170 Rash, history of tick bite, thrombocytopenia, and hypona

171 rolimus and exemestane (the most common were rash, hyperglycaemia, and stomatitis, which each affecte

172 g-related adverse events were diarrhea, skin rash, hyperglycemia, and night blindness.

173 ght contribute to the high frequency of skin rashes/hypersensitivity episodes experienced by astronau

174 Characteristics of vaccine-associated rash illness (VARI) and confirmed measles cases were com

175 d treatment of a previously unknown poxvirus rash illness in a renal transplant patient.

176 ies only after identification of heart block/rash in a child.

177 ntial diagnosis of bilateral lower extremity rash in patients with CD after infectious, malignant and

178 nvasive infection that presents as a diffuse rash in preterm and term infants.

179 llenge (PC) among children presenting with a rash in the course of amoxicillin treatment are currentl

180 congenital TORCH infections since there is a rash in the mother and there are commonly ocular abnorma

181 gs in patients with TORCH infections include rash in the mother during pregnancy and ocular findings

182 the necessary treatment of erlotinib-induced rash in the second- or third-line setting of metastatic

183 in seven (19%), anemia in four (10.8%), and rash in three (8.1%).

184 Rashes in the third trimester of pregnancy were associat

185 s were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammator

186 CH5126766 three times per week, and grade 3 rash (in two patients) and grade 3 creatinine phosphokin

187 Rash incidence and severity, time to maximal rash, time

188 she developed new bilateral lower extremity rash initially treated with levofloxacin for presumed ce

189 We defined CCC as a diffuse rash involving the body, extremities, face or scalp, and

190 pecially increased alkaline phosphatase, and rashes involving palms and soles.

191 classically diffuse, symmetric maculopapular rashes involving trunk and extremities.

192 median age, 11 years) and reported fever and rash less frequently, compared to cases from other US re

193 In comparison to other viral infections with rash-like symptoms, CXCL10 was highly elevated in MeV in

194 Immunofluorescence analysis of skin rash, lungs, lymph nodes, and ganglia revealed SVV ORF63

195 Rash, mostly of grade 1, was a common and transient adve

196 The condition's characteristic high fever, rash, mucositis, conjunctivitis, lymphadenopathy, and ex

197 oped based on duration of fever, severity of rash, multisystem involvement, and duration of symptoms

198 characteristic symptoms, including cutaneous rash, myalgia, and arthralgia, with the latter sometimes

199 often accompanied by fever (n = 15 [58%]) or rash (n = 14 [54%]).

200 matopoietic treatment-related AEs, including rash (n = 2) and transaminitis (n = 1), were observed in

201 of 210 patients with eosinophilia, including rash (n = 32), renal injury (n = 31), and liver injury (

202 espectively, were nausea (n = 13 and n = 6), rash (n = 4 and n = 1), hiccups (n = 4 and n = 1), mouth

203 were experienced by 18 patients (75%); only rash (n = 5; 21%) and pyrexia (n = 4; 17%) and occurred

204 se events were anaemia (n=2), fatigue (n=1), rash (n=1), and hypothyroidism (n=1).

205 rred in 11 (24%) of 46 patients and included rash (n=2 [4%]), pneumonia (n=2 [4%]), atrial fibrillati

206 n=440)-particularly generalised erythematous rash (n=334)-fever (n=333), leukopenia (n=217), and head

207 events, of which liver dysfunction (n=4) and rash (n=4) were most common.

208 Among Zika cases, rash (n=440)-particularly generalised erythematous rash

209 ommon reactions included cough (n=115, 16%), rash (n=66, 9%), and itching (n=37, 5%).

210 ], diarrhea [n = 84], vomiting [n = 20], and rash [n = 20]).

211 ], diarrhea [n = 52], vomiting [n = 28], and rash [n = 31]) and patients in the placebo group had 640

212 intractable grade 2 nausea [n=1] and grade 3 rash [n=1] in cohort 4, and grade 2 nausea and vomiting

213 ay (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]).

214 events: elevated liver transaminases, n = 1; rash, n = 1).

215 vaginal wounds, six reports of allergies or rashes, nine of urinary tract complaints (three with hyd

216 Neither vaccine viremia, rash, nor a significant antibody boost were observed fol

217 sulindac-erlotinib group, with an acne-like rash observed in 87% of participants receiving treatment

218 major toxicities, including absence of skin rash observed with other EGFR-directed agents.

219 Rash occurred more frequently in the ixazomib group than

220 Rash occurred more frequently with allopurinol (10% vers

221 rned home from Israel with measles; onset of rash occurred on September 30, 2018, 9 days after the ch

222 Severe rashes occurred in two patients, resulting in the early

223 es of measles were confirmed, with onsets of rash occurring between September 30, 2018, and July 15,

224 438 patients were referred to the IPESQ for rash occurring during pregnancy or for suspected fetal c

225 itoes that has caused outbreaks of fever and rash on islands in the Pacific and in the Americas.

226 Extensive maculopapular rash on the skin was consistent with graft-versus-host d

227 ented with generalised pruritic erythematous rash on trunk and extremities.

228 Atopic dermatitis, defined as an itchy rash on typical locations from birth to 6 years.

229 oup), diarrhoea (13 [10%] vs 14 [10%]), skin rash (one [1%] vs 22 [16%]), thromboembolic events (ten

230 sentation over the first week of illness was rash only (n=80).

231 infant (aged <12 months) measles cases with rash onset during March-September 2015 (wave 1) and Octo

232 npatient admission, 7-21 days before measles rash onset, for pneumonia or influenza (amOR: 4.5; CI, 2

233 d lasting from 4 days before to 4 days after rash onset.

234 cimens, and on respirators on days 5-8 after rash onset.

235 iologic link was hospitalized on day 5 after rash onset.

236 asles case-patients (23 detainees, 9 staff); rash onsets were during 6 May-26 June 2016.

237 inib vs two [1%] of 159 given gefitinib) and rash or acne (15 [9%] patients given afatinib vs five [3

238 rade 3 or 4 drug-related adverse events were rash or acne (31 [10%] of 320 patients in the afatinib g

239 atinib-related grade 3-4 adverse events were rash or acne (37 [16%] of 229 patients in LUX-Lung 3 and

240 h afatinib (16 [4%] vs none), and of grade 3 rash or acne with erlotinib (23 [6%] vs 41 [10%]).

241 4% vs. 2%), as were cutaneous events such as rash or eczema (in 37% vs. 19%, including serious events

242 Additionally, ten (36%) of 28 patients had rash or eschar, eight (29%) had lymphadenopathy, eight (

243 either strain of mice show any skin signs of rash or inflammation.

244 neutrophil transudation during colitis, skin rash or peritonitis.

245 ephalopathy, Merkel cell carcinoma, pruritic rash or trichodysplasia spinulosa.

246 ; 95% confidence interval (CI): 1.01, 1.66], rash (OR = 1.27; 95% CI: 1.02, 1.57), and earache (OR =

247 ory illness (OR = 1.37; 95% CI: 1.12, 1.67), rash (OR = 1.32; 95% CI: 1.05, 1.66), eye irritation (OR

248 reatment (after rash developed, per grade of rash), or no treatment unless severe (grade 3).

249 d toxic effects (grade 2 or worse diarrhoea, rash, or creatinine phosphokinase elevation).

250 cillin allergy, symptoms of pruritus without rash, or remote (>10 years) unknown reactions without fe

251 NV, ZIKV patients were more likely to have a rash (P < .001) and less likely to be febrile (P < .05)

252 orphology of cutaneous lesions, treatment of rash, peripheral blood eosinophil count, tumor response,

253 Rash, peripheral neuropathy, fatigue, alopecia, and naus

254 tify immune factors present during the acute rash phase of measles and associations with outcome and

255 solation, developed disseminated zoster with rash present for 1 day before being transferred to the i

256 erapy was started empirically at the time of rash presentation and continued for a median (interquart

257 C) is a challenging diagnosis due to various rash presentations.

258 skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine.

259 most commonly reported adverse effects were rash, pruritus, fatigue, and insomnia.

260 hemotherapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia).

261 ia and subsequent HSRs, including documented rash, renal injury, and liver injury.

262 igh levels of proinflammatory cytokines, and rash) resolved within 2 hours of AP1903 infusion.

263 ues and their mothers do not report having a rash, screening criteria must be revised in order to det

264 udinal prevalence of diarrhea, vomiting, and rash/sores.

265 %] of 154 vs ten [7%] of 152 with imatinib), rash (ten [6%] of 154 vs two [1%] of 152 with imatinib).

266 odds ratio = 9.6; 95% CI, 1.5-64.0), while a rash that lasted longer than 7 days (adjusted odds ratio

267 Skin rash, the most frequent adverse event, affected 74% of p

268 adverse event in the AZD8931 group was skin rash (three [20%] of 15 patients with available data vs

269 sented with fever, four had diffuse or focal rash, three had symptoms suggestive of neurological incl

270 Rash incidence and severity, time to maximal rash, time to resolution, and overall survival (OS) were

271 ng from a single bone lesion or trivial skin rash to an explosive disseminated disease.

272 hs, respectively) than those who received no rash treatment (6 months).

273 were ALT elevation (two [67%] of three) and rash (two [67%] of three) for patients with mantle cell

274 cute kidney injury (two), diarrhoea (three), rash (two), hyperglycaemia (one), loss of consciousness

275 une-related adverse events with two cases of rash, two of colitis, and one each of transaminitis, pan

276 a h2 is a major peanut allergen that induces rashes, vomiting, diarrhea, and anaphylactic shock.

277 Erlotinib-induced skin rash was associated with improved CFS (P = .01).

278 The occurrence or the grade of rash was not associated with a better survival in the Ge

279 Rash was not self-limiting.

280 oxicities were reported, a high incidence of rash was observed (all grades 82%, grade 3 36%).

281 ection between 8 and 9 days, and a petechial rash was observed with moribund ferrets.

282 Rash was present in 30 of 58 (52%), and conjunctival inj

283 Grade 3 rash was significantly higher in the no-treatment arm.

284 Rash was significantly more common in children than adul

285 Rash was significantly more common in children than adul

286 grade 3 to 4 treatment-related AEs; grade 3 rash was the only grade 3 to 4 event occurring in more t

287 ent in the phenytoin group (only one, severe rash, was attributable to phenytoin) compared with two (

288 ce rates for either recurrent eye disease or rash were 8%, 17%, and 25%, respectively.

289 ix classes based on temporal trajectories of rash were consistently identified in 2 population-based

290 First week mortality and history of rash were provided by the State medical teams.

291 dverse events (i.e., diarrhea, vomiting, and rash) were less common in the azithromycin-treated commu

292 erised by undifferentiated fever or afebrile rash, were missed.

293 The most common adverse event was rash, which developed in 1 participant with each sunscre

294 The most common adverse event was rash, which developed in 14 participants.

295 developed primary infection with viremia and rash, which resolved upon clearance of viremia, followed

296 Possible drug rash with eosinophilia and systemic symptoms (DRESS) syn

297 ), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS), ar

298 omegalovirus) were suspected to trigger drug rash with eosinophilia and systemic symptoms or GVHD.

299 died from chronic GVHD or unrecognized drug rash with eosinophilia and systemic symptoms, the others

300 out any other clinical finding; and afebrile rash with or without any other clinical finding.